Health Care · Services-Health Services

DCGO DocGo Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 182235958 filings
Russell 2000

DCGO at a glance

DocGo Inc. (DCGO, SEC CIK 1822359) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as May 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), DocGo Inc. (DCGO) reported revenue of $322.2 million (down 47.7% from FY2024) and a net loss of $182.4 million. Diluted EPS was -$1.84.
  • As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding DocGo Inc. (DCGO) shares worth $4.2 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Tendler Ely D on December 15, 2025 of 16,850 shares at $0.91 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$322.2M
−47.7% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
17 funds
$4.2M · −7 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Vertically integrated mobile healthcare platform combining in-home medical services, virtual care, and ambulance transport across US and UK
  • New in 2025: Acquisition of 50-state virtual care network with white-label telehealth, plus northeast mobile phlebotomy provider
  • Strategic shift: Decreasing reliance on government contracts (73% revenue in 2023 to 48% in 2025) by pivoting to payor partnerships, value-based models, and risk-sharing
  • Quantitative highlight: 3,568 total employees as of Dec 31, 2025, delivering 1.3M patient interactions, clinicians traveling 11M miles; Mobile Health segment NPS score 92
  • Noteworthy fact: Prevented estimated 91,000 unnecessary ER visits, saving US healthcare system $285M in costs since inception

Risk Factors

  • Regulatory risk: U.S. Department of Justice and Federal Trade Commission reviews could delay or block acquisitions, impacting DocGo’s growth strategy
  • Geopolitical risk: Exposure to uncertainty from U.S.-China relations, Ukraine war, Middle East conflict, Taiwan Strait tensions affecting operational costs and expansion
  • Operational risk: High upfront labor and supply costs in projects with large healthcare or government clients increase financial strain if economies of scale are not achieved
  • Competitive risk: Market disruption risk from large technology companies like Amazon (One Medical acquisition, Feb 2023), CVS (Signify Health acquisition, Mar 2023), Walmart entering telehealth
  • Financial risk: Heavy revenue concentration with one customer representing 33% of total revenues in 2025; contracts terminable with as little as 15 days’ notice

Management Discussion & Analysis

  • Revenue $322.2M in 2025, down 47.7% YoY from $616.6M in 2024, due to 71.3% decline in Mobile Health to $121.4M, Transportation up 3.8% to $200.8M
  • Operating margin -55.3% in 2025 vs 4.7% in 2024; cost of revenues ratio 69.4% vs 65.3%; operating expenses 85.9% of revenue vs 30.0% in 2024, driven by impairments
  • Best segment: Transportation Services revenue $200.8M (+3.8%), cost ratio improved to 68.4% from 69.1%; Worst segment: Mobile Health Services revenue $121.4M (-71.3%), cost ratio worsened to 70.9% from 63.6%
  • No explicit cash flow figures; capital allocation includes 3 acquisitions costing $21.1M in 2025 vs none in 2024; increased legal, technology, and bad debt expenses noted
  • Management expects Mobile Health revenues to decline in 2026 due to migrant contract wind-down; inflation and regulatory risks may affect margins and cash flow; plans continued AI & technology investment

AI summary of the DCGO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $73.4M, up 3.7% YoY from $70.8M, led by Transportation Services revenue $53.2M, up 6.2%
  • Cost-of-revenue margin 33.2% vs 25.6% YoY, with cost of revenues 66.8% vs 74.4%
  • Transportation Services strongest segment: revenue $53.2M vs $50.1M, 78,957 trips vs 71,541
  • Mobile Health Services weakest segment: revenue $20.2M, down 2.4% YoY, affected by migrant-services wind-down
  • Cash $19.1M, down $31.9M; operating cash flow used $17.5M versus $44.9M provided YoY
  • Outlook: lower 2026 Mobile Health revenue, further headcount reductions, collections and delayed growth spending amid near-term liquidity deficit

Risk Factors

  • Newly updated labor-cost risk: labor represented 77% of 2025 revenue, up from 68% in 2024
  • Operational risk: clinical labor shortages could require higher wages or more expensive temporary personnel
  • Regulatory risk: recent employee unionization and proposed federal labor-law changes could increase labor costs
  • Financial risk: fixed prospective payments limit DocGo’s ability to pass higher labor costs to customers

AI summary of the DCGO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CEO Lee Bienstock’s employment agreement expires December 31, 2026, creating an active succession process
  • Transition CEO service from January 1 through March 31, 2027, or later by mutual agreement
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 earnings results announced for quarter ended September 30, 2026
  • Management conference call scheduled November 9, 2026 at 5:00 p.m. Eastern Time

Item EX-99.2: Item EX-99.2

  • Q3 revenue $73.4M, up from $70.8M, reversing nine-month decline to $222.4M from $247.3M
  • Q3 adjusted gross margin 33.3%, up from 33.0%, while nine-month margin eased to 31.8% from 32.2%

Item EX-99.1: Item EX-99.1

  • Q3 revenue $73.4M, up from $70.8M, while adjusted EBITDA loss improved to $3.2M from $7.2M
  • GAAP gross margin reached 29.7% versus 20.0%, but GAAP net loss remained $18.1M
Filed Oct 5, 2026Full analysis →

Item 8.01: Other Events

  • Ambulnz begins managing Hicuity’s non-clinical operations effective October 1, 2026
  • Consulting Services Agreement closing conditions satisfied, activating the arrangement

Item 1.02: Termination of a Material Definitive Agreement

  • Existing revolving credit facility terminated October 1, 2026 before new Credit Agreement entry
  • All undrawn commitments canceled, eliminating access to the prior revolver

Item 3.02: Unregistered Sales of Equity Securities

  • Warrant issued to the administrative agent as consideration for entering the Credit Agreement
  • Potential warrant shares represent future equity dilution, with terms incorporated from Item 1.01

Item 1.01: Entry into a Material Definitive Agreement

  • Refinanced $52M existing debt and added $12.5M Term Loan B immediately
  • Additional $12.5M Term Loan C tied to merger completion, plus $25M delayed-draw capacity through December 31, 2027

AI summaries of DCGO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DCGO

Don't miss the next DCGO filing

  • Alerts as it files. A push when DCGO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DCGO, by share count.
  • Ask anything. An AI agent that reads every DCGO filing and answers with sources.

DCGO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Bienstock LeeFMay 12, 2026$0.59
Bienstock LeeFMar 30, 2026$0.57
Bienstock LeeFDec 15, 2025$0.91
Tendler Ely DSellDec 15, 2025$0.91
Sugrue StephenFDec 15, 2025$0.91
ROSENBERG NORMANFDec 15, 2025$0.91
ROSENBERG NORMANADec 12, 2025-
TRAVERS JAMES MADec 12, 2025-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$616.6M$322.2M
Operating Income-$28.7M-$178.0M
Net Income$6.9M$20.0M-$182.4M
Op. Margin-4.7%-55.3%
Net Margin-3.2%-56.6%
Balance Sheet
Total Assets$490.5M$455.6M$217.1M
Equity-$320.9M$144.0M
ROE-6.2%-126.7%
Per Share
EPS$0.06$0.18$-1.84
Cash Flow
Operating CF-$70.3M$34.5M
CapEx$7.6M$3.8M$4.5M

Source: XBRL data in DocGo Inc. (DCGO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DCGO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DCGO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202617$4.2M
Q2 202624$7.5M
Q1 202624$13.4M
Q4 202523$18.6M
Q3 202523$29.5M
Q2 202524$34.1M
Q1 202521$37.9M
Q4 202419$52.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 175 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DCGO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KOct 5, 2026Analysis-
8-KAug 17, 2026Analysis-
10-QAug 17, 2026Analysis
8-KJul 31, 2026Analysis-
8-KJul 2, 2026Analysis-
8-KJun 18, 2026Analysis-
4May 14, 2026-
10-QMay 11, 2026Analysis
8-KMay 11, 2026Analysis
8-KApr 22, 2026Analysis-
4Mar 31, 2026--
8-KMar 16, 2026Analysis-
10-KMar 16, 2026Analysis
8-KJan 30, 2026-
4Dec 16, 2025-
4Dec 16, 2025-
4Dec 16, 2025-
4Dec 16, 2025-
4Dec 16, 2025-
4Dec 16, 2025-
4Dec 16, 2025-
4Dec 16, 2025-

Related Health Care companies

All Health Care →

DCGO SEC filings: frequently asked questions

Which institutions hold DCGO stock?

As of September 30, 2026, the largest DocGo Inc. (DCGO) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.6 million), Renaissance Technologies LLC ($788,000), BlackRock ($557,000), AQR Capital Management ($246,000), State Street Corp ($163,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was DCGO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), DocGo Inc. (DCGO) reported revenue of $322.2 million (down 47.7% from FY2024) and a net loss of $182.4 million. Diluted EPS was -$1.84. The figures come from the XBRL data in the 10-K.

What are the main risks in DCGO's latest 10-K?

In the 10-K filed March 16, 2026, DocGo Inc. (DCGO) flagged: Regulatory risk: U.S. Department of Justice and Federal Trade Commission reviews could delay or block acquisitions, impacting DocGo’s growth strategy. Geopolitical risk: Exposure to uncertainty from U.S.-China relations, Ukraine war, Middle East conflict, Taiwan Strait tensions affecting operational costs and expansion. (AI summary of the Risk Factors section.)

What did DCGO report in its latest 8-K?

DocGo Inc. (DCGO) filed an 8-K on November 13, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). CEO Lee Bienstock’s employment agreement expires December 31, 2026, creating an active succession process.

What are the latest DCGO SEC filings?

DocGo Inc. (DCGO) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on May 14, 2026.

What is DCGO's SEC CIK number?

DocGo Inc. (DCGO)'s SEC Central Index Key (CIK) is 1822359. EDGAR lists every DCGO filing under that number.

Ask anything about DCGO

The research agent reads DCGO's filings, financials, insider trades and 13F holders, then answers with sources.